Engineered Picornavirus VPg-RNA Substrates: Analysis of a Tyrosyl-RNA Phosphodiesterase Activity by Rozovics, Janet M. et al.
Engineered Picornavirus VPg-RNA Substrates: Analysis of
a Tyrosyl-RNA Phosphodiesterase Activity
Janet M. Rozovics, Richard Virgen-Slane, Bert L. Semler*
Department of Microbiology and Molecular Genetics, School of Medicine, University of California Irvine, Irvine, California, United States of America
Abstract
Using poliovirus, the prototypic member of Picornaviridae, we have further characterized a host cell enzymatic activity
found in uninfected cells, termed ‘‘unlinkase,’’ that recognizes and cleaves the unique 59 tyrosyl-RNA phosphodiester bond
found at the 59 end of picornavirus virion RNAs. This bond connects VPg, a viral-encoded protein primer essential for RNA
replication, to the viral RNA; it is cleaved from virion RNA prior to its engaging in protein synthesis as mRNA. Due to VPg
retention on nascent RNA strands and replication templates, but not on viral mRNA, we hypothesize that picornaviruses
utilize unlinkase activity as a means of controlling the ratio of viral RNAs that are translated versus those that either serve as
RNA replication templates or are encapsidated. To test our hypothesis and further characterize this enzyme, we have
developed a novel assay to detect unlinkase activity. We demonstrate that unlinkase activity can be detected using this
assay, that this unique activity remains unchanged over the course of a poliovirus infection in HeLa cells, and that unlinkase
activity is unaffected by the presence of exogenous VPg or anti-VPg antibodies. Furthermore, we have determined that
unlinkase recognizes and cleaves a human rhinovirus-poliovirus chimeric substrate with the same efficiency as the
poliovirus substrate.
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Introduction
The presence of protein-nucleic acid covalent bonds is not
unusual in viral pathogens. Multiple virus families have a protein
covalently attached to their genomes; some examples include
Potyviridae, Adenoviridae, Nepoviridae, and Picornaviridae [for review, see
[1,2]]. In the case of picornaviruses this viral protein, termed VPg
(Viral Protein genome-linked), is located at the 59 end of all
nascent picornavirus genomes as a result of serving as a primer for
RNA synthesis [3,4,5,6,7,8,9,10,11].
The occurrence of protein-nucleic acid covalent bonds in
uninfected cells is slightly more novel. These linkages result from
the failure of a topoisomerase to dissociate properly from target
DNA [for review see [12]]. In such instances additional enzymes,
termed tyrosyl-DNA phosphodiesterases, are required to resolve
the phosphodiester bond formed with the nucleic acid. Currently,
there are two documented examples of these enzymes in
eukaryotic cells: tyrosyl-DNA phosphodiesterase 1 and tyrosyl-
DNA phosphodiesterase 2 (formerly TTRAP), which primarily
recognize and cleave 39 and 59 tyrosyl-DNA phosphodiester
bonds, respectively [13,14,15,16]. Interestingly, there is evidence
for a tyrosyl-RNA phosphodiesterase activity in eukaryotic cells.
Existence of this enzyme is demonstrated by the efficient removal
of the picornavirus protein VPg, which is attached to the genomic
RNA via an O
4-(59-Uridylyl)tyrosine bond, from the 59 end of the
viral genome (Figure 1) [17,18]. Although this activity has been
given several names in the literature, including unlinking enzyme
[18], VPg unlinkase [19], and uridylylpolynucleotide-(59 P-.O)-
tyrosine phosphodiesterase (Y-pUpN PDE) [20], in this manu-
script we will refer to the enzymatic activity as ‘‘unlinkase.’’
The identity of unlinkase is unknown, but the activity has been
partially characterized. Activity has been reported in wheat germ
extracts [17], mouse ascites Krebs II cells [21], rabbit reticulocyte
lysate [22,23,24], and in the nucleus and cytoplasm of HeLa cells
[17]. Unlinkase has the hallmarks of a bonafide enzyme, since the
activity is dependent on Mg
2+ or Mn
2+ [17,22] and is inhibited in
the presence of vanadate, SDS, Zn
2+ and EDTA [22,24].
Reducing agents, translation inhibitors, RNase, and protease
inhibitors do not appear to affect unlinkase activity [22]. It is
unknown whether unlinkase activity results from a single enzyme,
a complex of hetero- or homo-multimers, or an RNP complex
with the viral RNA. Partially purified preparations of the enzyme
have yielded low turnover numbers, suggesting that the purified
protein was only a component of a potential complex or that the
enzyme responsible possesses a very different function in the
uninfected cell and cleaving of the tyrosyl-RNA bond in
picornavirus genomic RNA is simply a minor role of the enzyme
[18]. It has also been demonstrated that the length of the attached
RNA, not the integrity of the VPg, is more important for efficient
unlinkase cleavage [18,19]. Unlinkase activity to date has been
described to recognize and cleave the VPg from the genomic RNA
of enteroviruses [17,18], cardioviruses [25], and aphthoviruses
[22]. The activity is very specific for a tyrosyl-RNA phosphodiester
bond, as a tyrosyl-DNA bond is not cleaved in the presence of
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e16559unlinkase [unpublished data, [20]], nor is the serine-RNA bond of
cowpea mosaic virus, a member of the Comovirinae virus subfamily
[21,26].
A key unresolved issue is the role of VPg cleavage from virion
RNA by unlinkase in the replication cycle of picornaviruses. VPg
is cleaved from picornaviral RNA genomes that are destined to
serve as templates for translation; the viral protein is retained on
templates for replication as well as genomes that are encapsidated
[8,27,28,29,30,31]. VPg, however, is not cleaved from VPg-pU
and VPg-pUpU substrates (which normally serve as primers for
replication during infection) [18,19]. We hypothesize that
unlinkase activity is utilized by picornaviruses to distinguish
templates for translation from those that are to serve as templates
for replication or that are encapsidated in virions for further
rounds of infection. This hypothesis would also support the
possibility that VPg has a role in encapsidation of the genome.
To test the hypothesis that unlinkase activity is required to
differentiate templates for translation from those to be used in
replication, the enzyme responsible for the activity must be
purified and identified. Despite intensive efforts from our lab and
other research groups, this is still a work in progress. However,
while the enzyme has not been identified, further characterization
of the activity has been accomplished. We have developed a novel
assay that visualizes migration of a
35S-methionine radiolabeled
VPg-RNA substrate generated in vivo to determine if unlinkase
activity is present. Here, we report that unlinkase activity can be
detected using this assay and confirm previous reports that the full-
length virion RNA is a much more efficient substrate than a VPg-
nonanucleotide substrate. We also demonstrate that this unique
activity remains unchanged over the course of a poliovirus
infection in HeLa cells and that it is unaffected by the presence
of exogenous VPg or anti-VPg antibodies. Furthermore, we have
determined that unlinkase recognizes and cleaves a human
rhinovirus-poliovirus chimeric substrate with the same efficiency
as the poliovirus substrate.
Materials and Methods
Extracts, partially-purified unlinkase fractions, synthetic
poliovirus VPg, and antibodies
Cytoplasmic extract for unlinkase analysis was prepared from
HeLa, NGP, SK-OV-3 and K562 cell lines. HeLa cells [32,33]
were grown in suspension culture in SMEM supplemented with
8% newborn calf serum (NCS), K562 cells [34] were grown in
DMEM supplemented with 10% fetal bovine serum (FBS), NGP
cells [35,36] were grown in DMEM supplemented with 20% FBS.
SK-OV-3 cell monolayers (American Type Culture Collection
number: HTB-77) were grown in RPMI media supplemented with
Figure 1. VPg-RNA covalent linkage and VPg sequences of wild type and mutated W1-VPg31 polioviruses. Schematic of the VPg-RNA
covalent linkage between the single tyrosine residue in poliovirus VPg and the first uridine at the 59 terminus of the genomic RNA (A). Image was
generated using ChemDraw software. The arrow indicates where unlinkase cleaves the bond. (B) VPg sequences of wild type poliovirus and W1-
VPg31 (wild type poliovirus mutated to encode two methionines in the VPg coding region).
doi:10.1371/journal.pone.0016559.g001
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to an S10 cytoplasmic preparation as described elsewhere [37].
However, extracts used for further unlinkase purification were not
subjected to micrococcal nuclease treatment, but were instead
used to prepare a ribosomal salt wash (RSW) fraction. To prepare
the RSW, HeLa cell S10 cytoplasmic extract was centrifuged at a
max RCF of 370,5006g for one hour at 4uC. The supernatant was
discarded and the pellet was resuspended in 1X hypotonic buffer
(20 mM HEPES, pH 7.4, 10 mM MgOAc, 1 mM DTT) and
adjusted to an OD260 nm of 240–480 units/ml (1 ml of sample
resuspended in 400 ml of 1X hypotonic buffer equals OD260 nm
units/ml). KCl was added to a final concentration of 0.5 M and
the mixture was incubated at 4uC for 15 minutes. The
resuspended pellet was then centrifuged again at a max RCF of
370,5006g for one hour at 4uC. The supernatant was collected
and dialyzed into unlinkase buffer (20 mM Tris-Cl, pH 7.5, 1 mM
DTT, 5% glycerol). Dialyzed fractions were stored at 280uC.
Micrococcal nuclease-treated rabbit reticulocyte lysate was
obtained from Promega.
To obtain cytoplasmic extracts from infected cells, HeLa cells in
suspension culture were pelleted and washed twice with 1X PBS.
Pelleted cells were resuspended in half of the required total volume
of serum-free SMEM and infected with wild type poliovirus at a
multiplicity of infection (MOI) of 20; adsorption took place at
room temperature for 30 minutes. After adsorption, 8% NCS,
remaining media and HEPES, pH 7.4 (final concentration
20 mM) were added; the infection was carried out at 37uC. S10
cytoplasmic extracts generated from poliovirus-infected HeLa cells
at zero, two, four and six hours post-infection, as well as a zero and
six hour time point from mock-infected HeLa cells, were prepared
as described [37], with the exception that they were not subjected
to treatment with microccocal nuclease.
To generate partially-purified, enriched unlinkase activity
fractions via cation-and-anion exchange chromatography (Frac-
tion CA), RSW was subjected to cation-exchange chromatography
(SP Sepharose FF, GE Healthcare), and proteins were eluted from
the column using increasing concentrations of NaCl in unlinkase
buffer. Protein fractions were dialyzed against unlinkase buffer and
analyzed for unlinkase activity. Peak fractions were pooled,
subjected to anion-exchange chromatography (AEC) (DEAE
Sepharose FF, GE Healthcare), and proteins were eluted using
increasing concentrations of NaCl in unlinkase buffer. Protein
fractions were dialyzed into unlinkase buffer and analyzed for
unlinkase activity; fractions containing peak activity were then
used in further assays.
To generate partially-purified, enriched unlinkase activity
fractions using sucrose gradient fractionation and anion-exchange
chromatography (Fraction SA), RSW was initially applied to one
of two gradients: 7%–47% sucrose w/w (20 mM Tris pH 7.5,
5 mM MgCl2, 100 mM KCl) or 15–30% sucrose w/w (20 mM
Tris pH 7.5, 5 mM MgCl2, 100 mM KCl). Gradient centrifuga-
tion was carried out in a Beckman SW41 rotor at 32,000 rpm for
three hours at 4uC. Fractions were collected, dialyzed into
unlinkase buffer, and analyzed for unlinkase activity. Fractions
exhibiting the highest levels of unlinkase activity from sucrose
gradients were pooled and subjected to anion-exchange chroma-
tography (DEAE Sepharose FF, GE Healthcare), and proteins
were eluted using increasing concentrations of NaCl in unlinkase
buffer. Protein fractions were dialyzed into unlinkase buffer and
analyzed for unlinkase activity; fractions containing peak activity
were then used in further assays.
Synthetic poliovirus VPg peptide was produced by BioBlocks,
San Diego, CA. This synthetic peptide was used to generate anti-
VPg polyclonal antibodies in rabbits (Bethyl Laboratories).
Cloning, transcription, and transfection of the human
rhinovirus 14-poliovirus S1-VPgR1 chimera
The site selection for the methionine mutations of the VPg
coding region of HRV14 was based on previously published work
[38,39,40]. The poliovirus cDNA plasmid, pT7PV1, was mutated
(Table 1: oligonucleotides 1–4) to flank the VPg coding sequence
with PpuMI and ApaI restriction sites. The native poliovirus VPg
coding region was excised using the engineered PpuMI and ApaI
restriction sites, replaced with the HRV14 VPg M[6,17] cartridge,
which consisted of two pairs of overlapping, complementary
oligonucleotides (Table 1: oligonucleotides 5–8) and cloned into
the gel-purified, linear template in a single ligation reaction. The
sequence of the final product, pT7-S1-VPgR1, was verified via
DNA sequencing using oligonucleotide 9 (Table 1).
The pT7-S1-VPgR1 template was linearized with EcoRI,
phenol/chloroform extracted, ethanol precipitated and tran-
scribed in vitro. Serial dilutions of the transcription reaction were
incubated with 1 mg/ml DEAE-dextran in TS buffer (19 mM
Tris-HCl, 4.4 mM KCl, 0.4 mM Na2HPO4, 137 mM NaCl,
490 mM MgCl2, 0.7 mM CaCl2, adjusted to pH 7.4) for 30
minutes at room temperature, and 250 ml of these mixtures were
used to transfect HeLa cell monolayers in 60 mm plates for 30
minutes at room temperature. Following transfection, the
monolayers were overlaid with DMEM supplemented with 10%
Table 1. Oligonucleotides used for cloning of S1-VPgR1.
Oligonucleotide # Name Oligonucleotide Sequence
1 pT7-PV1_PpuMI(+)5 9-TTTGCTGGACACCAGGGACCCTACACTGGTTTACCAAAC-39
2 pT7-PV1_PpuMI(-) 59-GTTTGGTAAACCAGTGTAGGGTCCCTGGTGTCCAGCAAA-39
3 pT7-PV1_ApaI(+)5 9-CAGCAAAGGTACAAGGGCCCGGGTTCGATTACGCAG-39
4 pT7-PV1_ApaI(-) 59-CTGCGTAATCGAACCCGGGCCCTTGTACCTTTGCTG-39
5 HRV14_P1(+)5 9-GACCCTATTCTGGTATGCCGCCTCACAATAAACTAA-39
6 HRV14_P1(-) 59-GCTTTTAGTTTATTGTGAGGCGGCATACCAGAATAGG-39
7 HRV14_P2(+)5 9-AAGCCCCAACTATGCGCCCAGTTGTTGTGCAAGGGCC-39
8 HRV14_P2(-) 59-CTTGCACAACAACTGGGCGCATAGTTGGG-39
9 3C_5628(-) 59-TCAAGATTGGTTCCTGCTTGAT-39
10 JT_5060(+)5 9-GAGAGAAACAGAAGATCCAA-39
doi:10.1371/journal.pone.0016559.t001
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transfection, plaques were isolated and used to infect HeLa cell
monolayers to generate viral stocks. Viral titers were determined
by plaque assay. The viral stocks were passaged three times, and
the P4 stock was used to generate the purified unlinkase substrate.
To verify that the VPg mutation was retained after transfection
and passaging of the mutant S1-VPgR1 virus, HeLa cell
monolayers were infected at an MOI of 25 for 5.5 hours and
total cellular RNA was extracted using TRI Reagent (Molecular
Research Center, Inc.) and subjected to RT-PCR (Table 1:
oligonucleotide 9) to produce a viral cDNA fragment. The cDNA
fragment was amplified by PCR (Table 1: oligonucleotides 9 and
10) and then subjected to DNA sequencing.
Preparation of picornavirus virion RNA substrates
The
35S-methionine-labeled virion RNA from the W1-VPg31
[38,39] and S1-VPgR1 viruses were prepared as follows: HeLa
cells in suspension culture were prepared for infection as described
above, with the exception of using methionine-free DMEM (MP
Biomedicals). The infected HeLa cells were starved of methionine
for two hours at 37uC after adsorption and then 1 mCi of
35S-
methionine was added. At six hours post-infection, cells were
pelleted and resuspended in RSB+Mg
2+ buffer (0.01 M NaCl,
0.01 M Tris-Cl, pH 7.5, 1.5 mM MgCl2). The resuspended pellet
was freeze-thawed five times and centrifuged again to pellet nuclei
and cellular debris. The supernatant was collected and the pellet
was washed again in RSB+Mg
2+ buffer, centrifuged, and the
resulting supernatant was pooled with the original supernatant.
The supernatant was centrifuged in a Beckman Ti 70 rotor at
24uC at 29,700 rpm for 3.5 hours to pellet virions. The resulting
supernatant was discarded, the pellet was resuspended in 0.1
buffer (0.1 M NaCl, 10 mM Tris-Cl, pH 7.5, 5 mM EDTA, 0.5%
SDS), applied to a 15–30% sucrose gradient (5 mM EDTA, 0.1 M
NaCl, 10 mM Tris-HCl, pH 7.5, 0.5% SDS), and centrifuged at
27,700 rpm in a Beckman SW41 rotor for 2.5 hours at 24uC.
Fractions of the gradient were collected and the radioactivity of
each fraction was determined by scintillation counting; peak
fractions were pooled and subjected to two rounds of phenol/
chloroform extraction and ethanol precipitation. The final volume
of the virion RNA prep was adjusted to 700 cpm/ml( ,0.15
pmol/ml).
The VPg-nonanucleotide substrate was generated by digesting
the full-length substrate with RNase T1 (200 units) for one hour at
37uC in TM Buffer (30 mM Tris-Cl, pH 7.5, 10 mM MgCl2).
This mixture was then directly added to an unlinkase source or
RNase A (Sigma) in assays.
Single-cycle viral growth analysis
Monolayers of HeLa cells [41] were washed twice with 1X PBS
and infected with either poliovirus or S1-VPgR1 virus at a
multiplicity of infection (MOI) of 20. Following a 30 minute
adsorption period at room temperature, cells were washed three
times with 1X PBS to remove unadsorbed virus and then overlaid
with DMEM supplemented with 10% FBS. Infection was carried
out at 37uC. At zero, two, four, and six hours post-infection, the
cells were scraped and collected with media. Cell suspensions were
subjected to five freeze–thaw cycles and total plaque-forming units
were determined via plaque assay.
Analysis of unlinkase activity and competition assays
For each experiment, the equivalent of 700 cpm (,0.15 pmol)/
reaction of radiolabeled substrate was used. VPg from the
poliovirus-rhinovirus chimera was differentially labeled compared
to W1-VPg31; to compensate, specific activities of the viral RNA
preparations were matched via addition of purified unlabeled W1-
VPg31 virion RNA to the radiolabeled W1-VPg31 virion RNA.
The final physical amounts of RNA for each reaction were equal.
Unless noted, the substrate was then incubated with 20 mgo f
protein from a source of unlinkase in the presence of 2 mM MgCl2
for 30 minutes. Reaction mixtures from either full-length or VPg-
nonanucleotide substrate experiments were resolved via 13.5%
Tris-tricine PAGE analysis. Gels were dried immediately after
electrophoresis. Following autoradiography using a phosphorima-
ger screen, results were analyzed using Quantity One software
(Bio-Rad).
For competition assays, 0.1, 0.5, or 1.0 mg of exogenous,
synthetic poliovirus VPg was pre-incubated with 20 mg of protein
from RSW (as an unlinkase source) for 15 minutes at 30uC before
the addition of
35S-methionine-labeled W1-VPg31 virion RNA
substrate; the reaction was incubated for an additional 10 minutes
at 30uC before the products were subjected to 13.5% Tris-tricine
PAGE analysis as previously described.
Results
Optimal assay conditions for detecting unlinkase activity
using full-length poliovirus virion RNA
35S-methionine-labeled substrate
We chose the approach of radiolabeling the mutant poliovirus
W1-VPg31 (Figure 1B) to clearly visualize liberation of VPg from
the VPg-RNA substrate. This approach also allows for inspection
of the cleaved VPg, as crude preparations of unlinkase from
cellular extracts contain a protease that degrades free VPg [24]. A
previously described method of detecting unlinkase activity via
measuring the partition of liberated RNA to the phenol phase is
problematic due to the potential degradation of VPg; the products
that result from proteolysis partition to the aqueous phase, possibly
leading to ambiguous interpretations of the data [22,24].
To determine optimal conditions for complete digestion of the
picornavirus substrate using our novel assay, we tested different
protein concentrations of an enriched unlinkase activity source
along with different reaction incubation times. Increasing
concentrations of an unlinkase-enriched protein fraction (Fraction
SA) were incubated with radiolabeled W1-VPg31 substrate
(Figure 2A), and we determined that 0.4 mg/ml, or 20 mg total,
was the optimal concentration for complete digestion of the full-
length poliovirus substrate (Figure 2A, lane 6) when the reaction
was allowed to incubate at 30uC for 30 minutes. To confirm that
30 minutes was the appropriate incubation time for unlinkase
activity on the radiolabeled substrate, a time-course assay using a
concentration of 0.4 mg/ml was carried out (Figure 2B). This assay
confirmed that 30 minutes was optimal for complete cleavage of
the substrate (Figure 2B, lane 8). Therefore, a concentration of
0.4 mg/ml of a partially-purified source of unlinkase incubated for
30 minutes at 30uC is sufficient to achieve complete cleavage of the
radiolabeled substrate.
To rule out the possibility that the unlinkase activity we
observed in our assay was the result of a non-specific nuclease, we
incubated our poliovirus substrate with RNase A (a single-strand
nuclease) and compared the migration of the resulting radiola-
beled VPg product to the VPg product that resulted when our
substrate was incubated with a source of unlinkase activity. W1-
VPg31 radiolabeled substrate was incubated with RSW (Figure 2C,
lane 2), protein from a partially-purified unlinkase fraction
(Fraction SA) (Figure 2C, lane 3), or RNase A (Figure 2C, lane
4). Treatment with RNase A would be predicted to produce a
VPg-pUp product because RNase cannot remove the final
attached nucleotide from the labeled VPg. Consistent with this
VPg Cleavage from Picornavirus RNA Substrates
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band that migrates with a slightly slower electrophoretic mobility
than the product of radiolabeled substrate treated with a source of
unlinkase (Figure 2C, compare lane 4 to lanes 2 and 3).
Additionally, significant levels of intact virion RNA are present
when incubated with highly enriched fractions of unlinkase
activity, further indicating that our VPg cleavage results are not
due to a non-specific nuclease (data not shown).
Full-length poliovirus genomic RNA is a more efficient
substrate than virion RNA treated with RNase T1
Other investigators have demonstrated that VPg attached to the
first nine nucleotides of the poliovirus genome, generated by
treatment of the full-length substrate with RNase T1, is a suitable,
if inefficient, substrate for unlinkase activity [18,19]. In our initial
studies, we utilized this VPg-nonanucleotide substrate to deter-
mine the presence and levels of unlinkase activity. Our rationale
for using this substrate was to visualize levels of liberated VPg
versus full-length VPg-RNA substrate in our Tris-tricine poly-
acrylamide gels, as full-length virion RNA should not be able to
enter into such a matrix. However, when compared to full-length,
we determined that the efficiency of VPg removal from the
truncated VPg-nonanucleotide substrate was noticeably reduced
(Figure 3A, compare lanes 1 and 5) using RSW as a source of
unlinkase activity. When treated with RNase T1, full-length
poliovirus virion RNA was observed to generate three labeled
products, with the slowest-migrating product being the most
prominent (Figure 3A, lane 2). It is likely that this larger product is
the VPg-nonanucleotide substrate and the less prominent bands
are the result of over-digestion of RNase T1, which primarily
recognizes and cleaves 39 single-stranded guanidine residues, but
can also cleave single-stranded adenosine residues if RNase T1 is
present in excess amounts. Interestingly, cleavage of this truncated
substrate is incomplete in the presence of saturating amounts of
RSW (Figure 3A, compare lanes 1 and 5). In fact, an intermediate
is observed (Figure 3A, lanes 3–5). By comparison (Figure 3B), full-
length poliovirus substrate that has not been pre-treated with
RNase T1 has the VPg efficiently cleaved from the virion RNA in
the presence of unlinkase; no intermediate products are observed
(Figure 3B, lanes 2–4). We also observed uncleaved full-length
virion RNA substrate (Figure 3B), although it was trapped at the
top of the separating gel and could not enter the matrix.
Additionally, at higher concentrations of RSW (Figure 3A, lane
5 and Figure 3B, lane 4), more free VPg was observed to be
degraded by an unidentified cellular protease [24]; we observe
reduced proteolytic degradation of liberated VPg as unlinkase
activity is further purified (data not shown). Based on these data,
we conclude that not only is full-length poliovirus virion RNA a
more efficient substrate for unlinkase activity than the VPg-
nonanucleotide substrate, but the shorter substrate forms an
intermediate that cannot be cleaved by unlinkase, confirming that
the length of the RNA plays a role in the activity of this enzyme.
Unlinkase activity remains unchanged during poliovirus
infection of HeLa cells
Although it has been reported that unlinkase activity was not
altered at late times after poliovirus infection [17,19], it was not
clear at what time during the infection unlinkase activity was
assayed or if a more sensitive assay could detect minor differences
in activity over a typical picornavirus infection. To address these
unresolved questions, we carried out a wild type poliovirus
infection of HeLa cells and generated cytoplasmic extracts from
infected cells at zero, two, four, or six hours post infection. These
extracts were then assayed for unlinkase activity (Figure 4). When
compared to the mock-infected cells harvested at zero and six
hours post infection (Figure 4, lanes 1, 2, 7, and 8), no measurable
difference in unlinkase activity was observed among the different
time points when 1 mg (Figure 4, lanes 3–6) or 5 mg (Figure 4, lanes
Figure 2. Optimal assay conditions for detecting unlinkase activity using full-length poliovirus virion RNA
35S-methionine labeled
substrate. A protein chromatography fraction enriched for unlinkase activity was incubated with full-length
35S-methionine radiolabeled W1-VPg 31
virion RNA substrate with either (A) increasing amounts of protein (0.01, 0.02, 0.04, 0.1, 0.2, 0.4, and 0.6 mg/ml) from an enriched source of unlinkase
activity (Fraction SA) at 30uC for 30 minutes or (B) increasing incubation time (0, 1, 2, 5, 10, 15, 20, and 30 minutes) with 0.4 mg/ml of protein from a
partially-purified fraction of unlinkase activity (Fraction SA) to determine optimal assay conditions for the full-length substrate. (C)
35S-methionine
radiolabeled W1-VPg 31 virion RNA substrate was mock-incubated (lane 1), incubated with 0.8 mg/ml RSW (lane 2), 0.4 mg/ml of protein from a
partially-purified fraction of unlinkase activity (Fraction SA) (lane 3), or one unit of RNase A (lane 4) to differentiate between non-specific nuclease
activity and authentic unlinkase activity.
doi:10.1371/journal.pone.0016559.g002
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that unlinkase activity remains unchanged over the time course of
a poliovirus infection, at least under the conditions we employed.
Extracts from different human cell lines have varying
levels of unlinkase activity
Using our newly-developed assay, we wanted to determine if
levels of unlinkase activity varied in extracts prepared from
different human cell lines. We tested cytoplasmic extracts from
human cells (Figure 5: HeLa, lanes 1–3, SK-OV-3, lanes 4–6,
NGP, lanes 7–9, K562, lanes 13–15) using our W1-VPg31
radiolabeled substrate, and discovered that unlinkase activity
varied among the human cell lines. The highest levels of unlinkase
activity were observed in HeLa cell (Figure 5, lanes 1–3) and K562
cell (Figure 5, lanes 13–15) cytoplasmic extract. NGP cytoplasmic
extract (Figure 5, lanes 7–9) exhibited lower levels of unlinkase
activity than HeLa or K562 cells; cytoplasmic extract from SK-
OV-3 cells (Figure 5, lanes 4–6) was observed to have the lowest
levels of unlinkase activity of the different human cell lines
examined. While levels of unlinkase activity differ, no correlation
can be made between the levels of unlinkase activity and infectivity
of the cell line. HeLa cells, with the highest levels of observed
unlinkase activity, and NGP cells, which were observed to have a
lower level of unlinkase activity, both support successful poliovirus
infection [42]. In contrast, viral growth is somewhat limited in SK-
OV-3 cells, which were observed to have low levels of unlinkase
activity [43]; poliovirus or rhinovirus infection of K562 cells,
which displayed high levels of unlinkase activity, results in a
persistent infection [44].
Rabbit reticulocyte lysate (RRL), which has been reported to
harbor unlinkase activity [3,22,24], was included as a control, but
we were unable to detect unlinkase activity using our assay
(Figure 5, lanes 10–12). This result was consistent over multiple
experiments and did not change if the RRL was not treated with
micrococcal nuclease prior to incubation with our radiolabeled
substrate (data not shown). We conclude from these experiments
that unlinkase activity varies in human cells but this variation in
activity does not appear to be related to the ability of a host cell to
support a successful picornaviral infection.
Exogenous VPg does not affect unlinkase activity
Studies using proteinase K to cleave the VPg protein on
picornavirus RNA, while leaving the tyrosyl-RNA phosphodiester
bond intact, indicate that the length of the attached VPg is not
important for unlinkase recognition [18,19]. However, these
experiments may not factor in VPg characteristics. VPg is a
highly basic protein that likely associates with the negatively-
charged backbone of the adjoining RNA molecule; it is possible
that this interaction is masking the tyrosyl-RNA phosphodiester
bond from unlinkase. In cleaving the majority of the connecting
VPg, and therefore increasing exposure of the tyrosyl-RNA
covalent bond, proteinase K may be enhancing unlinkase activity.
Based on the unique characteristics of VPg and its potentially
strong interaction with the adjoining picornavirus RNA, we
hypothesized that there is a component of unlinkase that
specifically recognizes and dissociates VPg from RNA in order
to unmask the tyrosyl-RNA bond. To test this hypothesis,
exogenous VPg was added as a potential competitor to reactions
Figure 3. Efficiency comparison of truncated versus full-length
35S-methionine labeled substrate.
35S-methionine radiolabeled W1-VPg
31 substrate that was treated with RNase T1 (A) or untreated (B) was incubated with increasing amounts of total protein from RSW (0, 5, 10, and
20 mg) as a source of unlinkase activity to demonstrate the efficiency of the truncated versus the full-length substrate.
doi:10.1371/journal.pone.0016559.g003
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lanes 2–4). We did not observe an effect on the efficiency of
cleavage of the full-length radiolabeled RNA substrate, only a
slower migration of the liberated radiolabeled VPg due to excess of
the co-migrating unlabeled small viral protein (Figure 6, lanes 2–
4). Additionally, antibodies specific for poliovirus VPg did not
interfere with the unlinkase reaction (data not shown). We
conclude that full-length VPg has no significant role in unlinkase
activity.
Unlinkase activity cleaves a human rhinovirus substrate
with the same efficiency as a poliovirus substrate
To determine if unlinkase activity can recognize and cleave a
human rhinovirus substrate, we developed a chimeric virus
consisting of a poliovirus genome that encodes a human rhinovirus
14 (HRV 14) VPg; the rhinovirus VPg was also mutated to encode
two methionine residues for radiolabeling. We developed this
chimeric virus, termed S1-VPgR1 (Figure 7A), due to the difficulty
of generating sufficient amounts of purified virion RNA from
human rhinovirus-infected HeLa cells. Growth kinetics deter-
mined that this virus chimera has a somewhat slower growth
phenotype at four hours post infection when compared to wild
type poliovirus in a single-cycle growth assay, but this difference is
eliminated by six hours post infection, when virions are harvested
for virus RNA purification (Figure 7B). S1-VPgR1 was used to
infect HeLa cells in the presence of
35S-methionine, and virion
RNA was purified. T1-treated virion RNA (Figure 7C) or full-
Figure 4. Unlinkase activity remains unchanged during poliovirus infection. HeLa cells were infected with wild type poliovirus and
cytoplasmic extracts were collected at 0 (lanes 3 and 9), 2 (lanes 4 and 10), 4 (lanes 5 and 11), or 6 (lanes 6 and 12) hours post-infection. 1 mg (lanes
1–6) or 5 mg (lanes 7–12) of total protein from these extracts was incubated with full-length
35S-methionine radiolabeled W1-VPg 31 virion RNA
substrate. No difference in activity was observed between the mock lanes (lanes 1, 2, 7, and 8) and the different time points collected during the
infection.
doi:10.1371/journal.pone.0016559.g004
Figure 5. Unlinkase activity in different cytoplasmic extracts
from human cell lines. Increasing amounts of total protein (0.1 mg/ml,
lanes 1, 4, 7, 10, and 13; 0.2 mg/ml, lanes 2, 5, 8, 11, and 14; 0.4 mg/ml,
lanes 3, 6, 9, 12, and 15) from cytoplasmic extracts from different cell
lines were incubated with
35S-methionine radiolabeled W1-VPg 31
virion RNA substrate. HeLa (lanes 1–3), SK-OV-3 (lanes 4–6), NGP (lanes
7–9), and K562 (lanes 13–15) are all human cell lines and have differing
levels of unlinkase activity; RRL (rabbit reticulocyte lysate) (lanes 10–12),
contrary to previous publications, did not exhibit unlinkase activity in
this assay (lanes 10–12).
doi:10.1371/journal.pone.0016559.g005
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VPgR1 radiolabeled substrates was incubated with an unlinkase
source to determine if cleavage efficiency differed between the two
viruses. RNase T1-generated substrates from both viruses
(Figure 7C) were incubated with 0, 5, 10 or 20 mg of total protein
from an enriched unlinkase activity source (Fraction CA), and no
significant difference in cleavage efficiency between the two
substrates was observed (Figure 7C compare lanes 4 and 8). Full-
length substrates from both viruses (Figure 7D) were incubated
with 0.5, 1, 2, 5, or 10 mg of total protein from the same enriched
unlinkase activity source, and again no significant differences in
cleavage between the two substrates were observed (Figure 7D
compare lanes 6 and 12). No difference was observed for unlinkase
cleavage of either substrate, leading to the conclusion that this
enzyme can recognize and cleave a human rhinovirus substrate.
Discussion
The linking of a protein to nucleic acid, ultimately resulting in a
phosphodiester bond, is not a unique event, as evidenced in several
virus families, prokaryotes, and eukaryotic cells. Enzymes that
recognize and cleave this bond, however, are far more unusual.
Such enzymes have been reported in prokaryotes, where proteins
are regulated by uridylylation. Uridylyl-removing and uridylyl-
transferase enzymes are involved in prokaryotic regulation of
glutamine synthetase [45] and galactose metabolism [46,47]. To
date, there have been two identified tyrosyl-DNA phosphodies-
terases in eukaryotes: tyrosyl-DNA phosphodiesterase 1 (Tdp1)
and tyrosyl-DNA phosphodiesterase 2 (formerly TTRAP), which
primarily recognize and cleave 39 and 59 tyrosyl-DNA phospho-
diester bonds, respectively [13,14,15,16]. No RNA-tyrosyl phos-
phodiesterases have been identified; yet, there is overwhelming
evidence that at least one such activity exists in mammalian cells as
demonstrated by the removal of the 59 terminal VPg from the
genomic RNAs of picornaviruses. It might be assumed that one of
the already-identified tyrosyl-DNA phosphodiesterases is also
responsible for this tyrosyl-RNA phosphodiesterase activity, but
this is not the case. We have determined that Tdp1 does not
recognize and cleave a picornavirus tyrosyl-RNA substrate, nor
does a source of unlinkase cleave a Tdp1 substrate (data not
shown). Additionally, multiple mass spectrometry analyses have
confirmed that neither Tdp1 nor TTRAP are found in any
enriched unlinkase activity-contained protein preparations (data
not shown). These findings are not surprising as it has been
previously demonstrated that unlinkase recognizes and cleaves a
very specific 59 tyrosyl-RNA bond; it cannot cleave a synthetically
generated 59 tyrosyl-DNA bond [20], nor can it cleave a serine-
RNA bond [21,26].
Although the identity of unlinkase remains to be determined, its
activity has been partially characterized. It is still unknown if this
enzymatic activity is the result of a single protein, a multi-protein
complex, or even possibly a ribonucleoprotein complex. We have
confirmed that a longer length of the attached RNA to VPg
increases the efficiency of the unlinkase activity. Why increasing
the length of the genomic RNA increases the efficiency is currently
unknown. It is possible that other sequences and/or structures in
the picornavirus genome enhance recognition of the substrate
bond, or that a longer RNA length is required for proper docking
of the enzyme (potentially a complex). We explored the possibility
of unlinkase activity resulting from the picornavirus genome acting
as a ribozyme, but we could find no evidence to support this
hypothesis (data not shown). Regardless of the mechanism, a host
factor contributes to unlinkase activity and still must be identified.
We have determined that unlinkase can successfully recognize
and cleave a picornaviral chimeric substrate that has a human
rhinovirus 14 VPg covalently attached to the poliovirus genome.
When accounting for the specific activity of the two picornavirus
substrates, a protein fraction enriched for unlinkase activity had no
preference for either the poliovirus or rhinovirus-poliovirus
chimeric substrate, even though the amino acid sequence identity
between the two VPg sequences is only 44%. Further supporting
the conclusion that the covalently attached RNA is more
important than the VPg protein is our data demonstrating that
unlinkase activity remains unchanged in the presence of exogenous
synthetic VPg as well as anti-VPg antibodies. The exogenous VPg
was unable to sequester the unlinkase activity, leading to the
conclusion that VPg alone, the product of this reaction, does not
interact with the component(s) of the activity.
We wanted to determine if the level of unlinkase activity in
extracts derived from different human cell lines was altered when
compared to HeLa cell extract. Depending on the cell line tested,
it was determined that activity did vary. K562, a human
hematopoietic cell line, has unlinkase activity levels comparable
to those in HeLa cells. Cytoplasmic extracts from SK-OV-3 cells,
Figure 6. Exogenous poliovirus VPg does not affect unlinkase
activity. Increasing amounts (0, 0.1, 0.5, and 1.0 mg) of exogenous
synthetic poliovirus VPg peptide was added to full-length
35S-
methionine-labeled substrate W1-VPg 31 virion RNA and RSW (0.4 mg/
mlo r2 0 mg total) as an unlinkase source. Neither the addition of
exogenous viral peptide (lanes 2–4) nor the addition of anti-VPg
antibodies had an effect on unlinkase activity (data not shown).
doi:10.1371/journal.pone.0016559.g006
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cell line, had significantly less unlinkase activity compared to HeLa
cells. It is noteworthy that unlinkase activity levels cannot be
correlated to picornavirus infectivity; the significance of the altered
levels of unlinkase activity in the cell lines tested remains to be
determined. As a control, we also tested activity in rabbit
reticulocyte lysate (RRL). Multiple groups have reported the
presence of unlinkase activity in RRL, yet we have been unable to
repeat these results using our assay and conditions. Our work is
not the first indication that RRL has limited unlinkase activity
during short incubation times [24,48]. It is possible that
significantly more protein from RRL than from human cell
extract is necessary to achieve cleavage of the viral substrate (a
plausible explanation as partial purification of the enzyme using
RRL as a source has not been reported) or that a much longer
incubation time is needed to observe cleavage of the substrate.
We explored the possibility that unlinkase activity might vary
over the course of a picornavirus infection of HeLa cells. Our
results were somewhat surprising, as one might expect unlinkase
activity to decrease as the virus assumes control over the cellular
transcription and translational machinery. In addition to the
expectation that protein(s) responsible for unlinkase activity might
be degraded and not replenished, we also considered the
possibility that the activity would decrease as the infection
progressed, providing more viral substrate and leaving less
unlinkase available to act upon exogenous radiolabeled substrate.
However, this was not what was observed, as unlinkase activity
remained constant throughout the course of poliovirus infection. It
is possible that unlinkase levels do not change over the course of
the infection, but that picornavirus genomic RNA may be
unavailable to unlinkase activity due to association with membra-
nous vesicles in replication complexes, or through an association
with viral capsid proteins.
The rationale for why unlinkase activity remains unchanged
over the course of a typical poliovirus infection may offer insight
into the role of unlinkase activity in the replication cycle of the
virus. We hypothesize that unlinkase activity is usurped by the
virus to distinguish templates for translation versus those destined
to become replication templates or to be encapsidated. If unlinkase
activity is used for this purpose, this mechanism may only be
required early in the infection when it is crucial that templates are
available for viral protein synthesis. It has been demonstrated that
poliovirus genomes undergo a successful round of translation
before being utilized as a template for replication [49,50]. It is
currently unknown if unlinkase cleaves VPg from the genomic
RNA before or after the initiation of translation, but it has been
reported that ribosomes can associate with full-length VPg-RNA,
although this study used RRL as a source of translation extract
[48]. RRL was later shown to produce aberrant protein products
when programmed with poliovirus virion RNA [51] and is
suspected to be deficient in unlinkase activity (Figure 5, lanes 10-
12). VPg removal from viral RNA could conceivably be a marker
to distinguish a template that will maintain, at least initially,
sustained levels of viral protein synthesis and RNA replication.
Such efficiency may be more important prior to the peak of RNA
replication, when viral proteins must carry out the initial rounds of
replication of the picornavirus genome. Once a basal threshold of
viral proteins sufficient for maximal viral RNA synthesis is
produced, it may not be crucial to maintain efficient translation
of viral proteins. An explanation for how picornaviruses protect
RNA replication templates and full-length genomes for encapsida-
tion from VPg removal from virion RNA is via coupling RNA
replication and encapsidation, as these viral processes have been
demonstrated to be coupled in vitro [32,50,52,53,54]; it is feasible
that the capsid proteins shield the nascent viral genomic RNA
from unlinkase activity.
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